Sistema de Información Esencial en Terapéutica y Salud


Última actualización: 12/8/2020
SIETES contiene 93083 citas

 1 a 20 de 79 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Anónimo. FDA expands recall of potentially contaminated valsartan. DIA Daily 2018:8 de agosto. [Ref.ID 102753]
3.Tiene citas relacionadas Cita con resumen
Chang S-S, Stuckler D, Yip P, Gunnell D. Impact of 2008 global economic crisis on suicide: time trend study in 54 countries. BMJ 2013;347:13. [Ref.ID 96258]
4.Tiene citas relacionadas
Hawton K, Haw C. Economic recession and suicide. BMJ 2013;347:9. [Ref.ID 96256]
5.Tiene citas relacionadas Cita con resumen
Lozano R, Wang H, Foreman KJ, Rajaratnam JK, Naghavi M, Marcus JR, Dwyer-Lindgren L, Lofgren KT, Phillips D, Atkinson C, Lopez AD, Murray CJL. Progress towards Millennium Development Goals 4 and 5 on maternal and child mortality: an updated systematic analysis. Lancet 2011;378:1139-65. [Ref.ID 91511]
6.Tiene citas relacionadas
Byass P, Graham WJ. Grappling with uncertainties along the MDG trail. Lancet 2011;378:1119-20. [Ref.ID 91510]
7.Tiene citas relacionadas Cita con resumen
Rajaratnam JK, Marcus JR, Levin-Rector A, Chalupka AN, Wang H, Dwyer L, Costa M, López AD, Murray CJL. Worldwide mortality in men and women aged 15-59 years from 1970 to 2010: a systematic analysis. Lancet 2010;375:1704-20. [Ref.ID 88504]
8.Tiene citas relacionadas
Koyanagi A, Shibuya K. What do we really know about adult mortality worldwide?. Lancet 2010;375:1668-70. [Ref.ID 88501]
9. Cita con resumen
Hogan MC, Foreman KJ, Nagavi M, Ahn SY, Wang M, Makela SM, López AD, Lozano R, Murray CJL. Maternal mortality for 181 countries, 1980-2008: a systematic analysis of progress towards Millennium Development Goal 5. Lancet 2010;375:1609-23. [Ref.ID 88495]
10. Cita con resumen
Watson R. 15% of antibiotic sales in Greece are over the counter. BMJ 2010;340:886-7. [Ref.ID 88385]
12.Tiene citas relacionadas
Brekke M, Gjelsvik B. Effectiveness of secondary prevention programmes in CHD. Authors' reply. Lancet 2009;373:1671. [Ref.ID 85869]
13.Tiene citas relacionadas
Clark AM, Dalal HM, Dafoe W, Stone JA, Lewin RJP. Effectiveness of secondary prevention programmes in CHD. Lancet 2009;373:1671. [Ref.ID 85868]
14. Cita con resumen
Siva N. The drug price is right - or is it?. Lancet 2009;373:1326-7. [Ref.ID 85660]
15.Tiene citas relacionadas Cita con resumen
Kotseva K, Wood D, De Backer G, De Bacquer D, Pyörälä K, Keil U, for the EUROASPIRE Study Group. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009;373:929-40. [Ref.ID 85473]
16.Tiene citas relacionadas Cita con resumen
Brekke M, Gjelsvik B. Secondary cardiovascular risk prevention - we can do better. Lancet 2009;373:873-5. [Ref.ID 85465]
17. Cita con resumen
Raschi E, Poluzzi E, Zuliani C, Muller A, Goossens H, De Ponti F. Exposure to antibacterial agents with QT liability in 14 European countries: trends over and 8-year period. Br J Clin Pharmacol 2009;67:88-98. [Ref.ID 84983]
18. Cita con resumen
Schofield I. Sanofi-Aventis, Teva and Lipitor top EU 2007 rankings. Scrip 2008;3421/22:34. [Ref.ID 84793]
19. Cita con resumen
Jagger C, Gillies C, Moscone F, Cambois E, Van Oyen H, Nusselder W, Robine J-M, and the EHLEIS team. Inequalities in healthy life years in the 25 countries of the European Union in 2005: a cross-natinoal meta-regression analysis. Lancet 2008;372:2124-31. [Ref.ID 84787]
20. Cita con resumen
Viola R, Benkó R, Nagy G, Soós G. National trend of antidepressant consumption and its impact on suicide rate in Hungary. Pharmacoepidemiol Drug Saf 2008;17:401-5. [Ref.ID 82715]
Seleccionar todas
 1 a 20 de 79 siguiente >>